If there is going to be a delay in uptake due to the time cycles of hospital committees then the BARDA procurement in full or staged announcements will be much appreciated by management and the market. This quarter sales figures will be very interesting and telling.
IMO, the round figure retail pricing announced by management was a strategic announcement, to market the real price they will push. First of all to the existing surgeons/hospitals that have used ReCell in the trials and who are very keen to adopt it, and to the potentially new surgeons and hospitals.
The other possible spanner in the works could be the recruitment of the quality sales staff. How many are they taking on, 10?
Ann: Randomized Controlled Clinical Study of RECELL System, page-21
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.04 |
Change
-0.040(1.30%) |
Mkt cap ! $212.6M | |||
| Open | High | Low | Value | Volume |
| $3.08 | $3.08 | $3.00 | $195.5K | 64.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5553 | $3.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.04 | 888 | 1 |
View Market Depth
| Last trade - 14.30pm 27/09/2024 (20 minute delay) ? |
| AVH (ASX) Chart |